Home › Trials › NCT06494241

Improving lung cancer care in small and middle-tier cities

A Multi-Center Study to Evaluate the Guideline Education of Oncology Departments in Small/Middle Tier Cities and County Hospitals for Diagnosis and Treatment Improvement in Patients With Metastatic Non-small Cell Lung Cancer

Observational AstraZeneca · NCT06494241

This study looks at how well new treatment guidelines for lung cancer are being followed in small and mid-sized cities to see if they can help improve care for patients with advanced lung cancer.

Quick facts

Study typeObservational
Enrollment1000 (estimated)
Ages18 Years and up
SexAll
SponsorAstraZeneca Industry-sponsored
Locations48 sites (Anning and 47 other locations)
Trial IDNCT06494241 on ClinicalTrials.gov

What this trial studies

This observational study aims to evaluate the patterns of molecular testing and treatment in patients with metastatic non-small cell lung cancer (NSCLC) following the implementation of quality improvement practices in oncology departments. The focus is on small and middle-tier cities and county hospitals, where standardized education and clinical practice guidelines for lung cancer treatment are introduced. By assessing these patterns, the study seeks to identify gaps in care and improve outcomes for patients diagnosed with metastatic NSCLC.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older with newly diagnosed or recurrent metastatic NSCLC.

Not a fit: Patients who are currently participating in other intervention clinical trials or have previously enrolled in another QIP study may not benefit from this study.

Why it matters

Potential benefit: If successful, this project could enhance the quality of lung cancer care and treatment outcomes for patients in underserved areas.

How similar studies have performed: While this approach is focused on quality improvement in specific geographic areas, similar studies have shown success in enhancing cancer care through standardized practices.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Age ≥18 years, at the time of signing the informed consent.
* ECOG performance status 0-2.
* Newly pathologic diagnosed metastatic NSCLC (clinical stage IV) or recurrent metastatic NSCLC.

Exclusion Criteria:

* Be participating in other intervention clinical trials.
* Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
* Previous enrolment in the other QIP study.

Where this trial is running

Anning and 47 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Carcinoma, Non-Small-Cell LungLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.